Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
22.60
+0.60 (2.73%)
Mar 27, 2026, 5:35 PM CET
Market Cap885.81M +16.3%
Revenue (ttm)84.66M +2,060.3%
Net Income45.91M
EPS1.14
Shares Out40.26M
PE Ratio19.25
Forward PE5.61
Dividendn/a
Ex-Dividend Daten/a
Volume17,145
Average Volume17,807
Open22.00
Previous Close22.00
Day's Range22.00 - 22.60
52-Week Range18.90 - 27.80
Beta0.09
RSI54.61
Earnings DateMar 27, 2026

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 201
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements